Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA LE MODIFICHE in fondo alla pagina
Bicocca Open Archive
Background: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients with HFrEF in addition to baseline treatment with specific doses and combinations of disease-modifying therapies. Methods: We performed a post-hoc analysis of the EMPEROR-Reduced randomised, double-blind, parallel-group trial, which took place in 520 centres (hospitals and medical clinics) in 20 countries in Asia, Australia, Europe, North America, and South America. Patients with New York Heart Association (NYHA) classification II–IV with an ejection fraction of 40% or less were randomly assigned (1:1) to receive the addition of either oral empagliflozin 10 mg per day or placebo to background therapy. The primary composite outcome was cardiovascular death and heart failure hospitalisation; the secondary outcome was total heart failure hospital admissions. An extended composite outcome consisted of inpatient and outpatient HFrEF events was also evaluated. Outcomes were analysed according to background use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs), as well as β blockers and mineralocorticoid receptor antagonists (MRAs) at less than 50% or 50% or more of target doses and in various combinations. This study is registered with ClinicalTrials.gov, NCT03057977. Findings: In this post-hoc analysis of 3730 patients (mean age 66·8 years [SD 11·0], 893 [23·9%] women; 1863 [49·9%] in the empagliflozin group, 1867 [50·1%] in the placebo group) assessed between March 6, 2017, and May 28, 2020, empagliflozin reduced the risk of the primary outcome (361 in 1863 participants in the empagliflozin group and 462 of 1867 in the placebo group; HR 0·75 [95% CI 0·65–0·86]) regardless of background therapy or its target doses for ACE inhibitors or ARBs at doses of less than 50% of the target dose (HR 0·85 [0·69–1·06]) and for doses of 50% or more of the target dose (HR 0·67 [0·52–0·88]; pinteraction=0·18). A similar result was seen for β blockers at doses of less than 50% of the target dose (HR 0·66 [0·54–0·80]) and for doses of 50% or more of the target dose (HR 0·81 [0·66–1·00]; pinteraction=0·15). Empagliflozin also reduced the risk of the primary outcome irrespective of background use of triple therapy with an ACE inhibitor, ARB, or ARNI plus β blocker plus MRA (given combination HR 0·73 [0·61–0·88]; not given combination HR 0·76 [0·62–0·94]; pinteraction=0·77). Similar patterns of benefit were observed for the secondary and extended composite outcomes. Empagliflozin was well tolerated and rates of hypotension, symptomatic hypotension, and hyperkalaemia were similar across all subgroups. Interpretation: Empagliflozin reduced serious heart failure outcomes across doses and combinations of disease-modifying therapies for HFrEF. Clinically, these data suggest that empagliflozin might be considered as a foundational therapy
Verma, S., Dhingra, N., Butler, J., Anker, S., Ferreira, J., Filippatos, G., et al. (2022). Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. THE LANCET DIABETES & ENDOCRINOLOGY, 10(1), 35-45 [10.1016/S2213-8587(21)00292-8].
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Verma S.;Dhingra N. K.;Butler J.;Anker S. D.;Ferreira J. P.;Filippatos G. S.;Januzzi J. L.;Lam C. S. P.;Sattar N.;Peil B.;Nordaby M.;Brueckmann M.;Pocock S. J.;Zannad F.;Packer M.;Packer M.;Butler J.;Pocock S.;Zannad F.;Ferreira J. P.;Brueckmann M.;George J.;Jamal W.;Welty F. K.;Palmer M.;Clayton T.;Parhofer K. G.;Pedersen T. R.;Greenberg B.;Konstam M. A.;Lees K. R.;Carson P.;Doehner W.;Miller A.;Haas M.;Pehrson S.;Komajda M.;Anand I.;Teerlink J.;Rabinstein A.;Steiner T.;Kamel H.;Tsivgoulis G.;Lewis J.;Freston J.;Kaplowitz N.;Mann J.;Petrie J.;Perrone S.;Nicholls S.;Janssens S.;Bocchi E.;Giannetti N.;Zhang J.;Spinar J.;Seronde M. -F.;Boehm M.;Merkely B.;Chopra V.;Senni M.;Taddi S.;Tsutsui H.;Choi D. -J.;Chuquiure E.;La Rocca H. P. B.;Ponikowski P.;Juanatey J. R. G.;Squire I.;Januzzi J.;Pina I.;Bernstein R.;Cheung A.;Green J.;Kaul S.;Lam C.;Lip G.;Marx N.;McCullough P.;Mehta C.;Rosenstock J.;Sattar N.;Scirica B.;Shah S.;Wanner C.;Aizenberg D.;Cartasegna L.;Colombo Berra F.;Colombo H.;Fernandez Moutin M.;Glenny J.;Alvarez Lorio C.;Anauch D.;Campos R.;Facta A.;Fernandez A.;Ahuad Guerrero R.;Lobo Marquez L.;Leon de la Fuente R. A.;Mansilla M.;Hominal M.;Hasbani E.;Najenson M.;Moises Azize G.;Luquez H.;Guzman L.;Sessa H.;Amuchastegui M.;Salomone O.;Perna E.;Piskorz D.;Sicer M.;Perez de Arenaza D.;Zaidman C.;Nani S.;Poy C.;Resk J.;Villarreal R.;Majul C.;Smith Casabella T.;Sassone S.;Liberman A.;Carnero G.;Caccavo A.;Berli M.;Budassi N.;Bono J.;Alvarisqueta A.;Amerena J.;Kostner K.;Hamilton A.;Begg A.;Beltrame J.;Colquhoun D.;Gordon G.;Sverdlov A.;Vaddadi G.;Wong J.;Coller J.;Prior D.;Friart A.;Leone A.;Vervoort G.;Timmermans P.;Troisfontaines P.;Franssen C.;Sarens T.;Vandekerckhove H.;Van De Borne P.;Chenot F.;De Sutter J.;De Vuyst E.;Debonnaire P.;Dupont M.;Pereira Dutra O.;Canani L. H.;Vieira Moreira M.;de Souza W.;Backes L. M.;Maia L.;De Souza Paolino B.;Manenti E. R.;Saporito W.;Villaca Guimaraes Filho F.;Franco Hirakawa T.;Saliba L. A.;Neuenschwander F. C.;de Freitas Zerbini C. A.;Goncalves G.;Goncalves Mello Y.;Ascencao de Souza J.;Beck da Silva Neto L.;Bocchi E. A.;Da Silveira J.;de Moura Xavier Moraes Junior J. B.;de Souza Neto J. D.;Hernandes M.;Finimundi H. C.;Sampaio C. R.;Vasconcellos E.;Neves Mancuso F. J.;Noya Rabelo M. M.;Rodrigues Bacci M.;Santos F.;Vidotti M.;Simoes M. V.;Gomes F. L.;Vieira Nascimento C.;Precoma D.;Helfenstein Fonseca F. A.;Ribas Fortes J. A.;Leaes P. E.;Campos de Albuquerque D.;Kerr Saraiva J. F.;Rassi S.;Alves da Costa F. A.;Reis G.;Zieroth S.;Dion D.;Savard D.;Bourgeois R.;Constance C.;Anderson K.;Leblanc M. -H.;Yung D.;Swiggum E.;Pliamm L.;Pesant Y.;Tyrrell B.;Huynh T.;Spiegelman J.;Lavoie J. -P.;Hartleib M.;Bhargava R.;Straatman L.;Virani S.;Costa-Vitali A.;Hill L.;Heffernan M.;Khaykin Y.;Ricci J.;Senaratne M.;Zhai A.;Lubelsky B.;Toma M.;Yao L.;McKelvie R.;Noronha L.;Babapulle M.;Pandey A.;Curnew G.;Lavoie A.;Berlingieri J.;Kouz S.;Lonn E.;Chehayeb R.;Zheng Y.;Sun Y.;Cui H.;Fan Z.;Han X.;Jiang X.;Tang Q.;Zhou J.;Zheng Z.;Zhang X.;Zhang N.;Zhang Y.;Shen A.;Yu J.;Ye J.;Yao Y.;Yan J.;Xu X.;Wang Z.;Ma J.;Li Y.;Li S.;Lu S.;Kong X.;Song Y.;Yang G.;Yao Z.;Pan Y.;Guo X.;Sun Z.;Dong Y.;Zhu J.;Peng D.;Yuan Z.;Lin J.;Yin Y.;Jerabek O.;Burianova H.;Fiala T.;Hubac J.;Ludka O.;Monhart Z.;Vodnansky P.;Zeman K.;Foldyna D.;Krupicka J.;Podpera I.;Busak L.;Radvan M.;Vomacka Z.;Prosecky R.;Cifkova R.;Durdil V.;Vesely J.;Vaclavik J.;Cervinka P.;Linhart A.;Brabec T.;Miklik R.;Bourhaial H.;Olbrich H. -G.;Genth-Zotz S.;Kemala E.;Lemke B.;Bohm M.;Schellong S.;Rieker W.;Heitzer T.;Ince H.;Faghih M.;Birkenfeld A.;Begemann A.;Ghanem A.;Ujeyl A.;von Haehling S.;Dorsel T.;Bauersachs J.;Prull M.;Weidemann F.;Darius H.;Nickenig G.;Wilke A.;Sauter J.;Rauch-Kroehnert U.;Frey N.;Schulze C. P.;Konig W.;Maier L.;Menzel F.;Proskynitopoulos N.;Ebert H. -H.;Sarnighausen H. -E.;Dungen H. -D.;Licka M.;Stellbrink C.;Winkelmann B.;Menck N.;Lopez-Sendon J. L.;de la Fuente Galan L.;Delgado Jimenez J. F.;Manito Lorite N.;Perez de Juan Romero M.;Galve Basilio E.;Cereto Castro F.;Gonzalez Juanatey J. R.;Gomez J. J.;Sanmartin Fernandez M.;Garcia-Moll Marimon X.;Pascual Figal D.;Bover Freire R.;Bonnefoy Cudraz E.;Jobbe Duval A.;Tomasevic D.;Habib G.;Isnard R.;Picard F.;Khanoyan P.;Dubois-Rande J. -L.;Galinier M.;Roubille F.;Alexandre J.;Babuty D.;Delarche N.;Berneau J. -B.;Girerd N.;Saxena M.;Rosano G.;Yousef Z.;Clifford C.;Arden C.;Bakhai A.;Boos C.;Jenkins G.;Travill C.;Price D.;Koenyves L.;Lakatos F.;Matoltsy A.;Noori E.;Zilahi Z.;Andrassy P.;Kancz S.;Simon G.;Sydo T.;Vorobcsuk A.;Kiss R. G.;Toth K.;Szakal I.;Nagy L.;Barany T.;Nagy A.;Szolnoki E.;Chopra V. K.;Mandal S.;Rastogi V.;Shah B.;Mullasari A.;Shankar J.;Mehta V.;Oomman A.;Kaul U.;Komarlu S.;Kahali D.;Bhagwat A.;Vijan V.;Ghaisas N. K.;Mehta A.;Kashyap J.;Kothari Y.;TaddeI S.;Scherillo M.;Zaca V.;Genovese S.;Salvioni A.;Fucili A.;Fedele F.;Cosmi F.;Volpe M.;Mazzone C.;Esposito G.;Doi M.;Yamamoto H.;Sakagami S.;Oishi S.;Yasaka Y.;Tsuboi H.;Fujino Y.;Matsuoka S.;Watanabe Y.;Himi T.;Ide T.;Ichikawa M.;Kijima Y.;Koga T.;Yuda S.;Fukui K.;Kubota T.;Manita M.;Fujinaga H.;Matsumura T.;Fukumoto Y.;Kato R.;Kawai Y.;Hiasa G.;Kazatani Y.;Mori M.;Ogimoto A.;Inoko M.;Oguri M.;Kinoshita M.;Okuhara K.;Watanabe N.;Ono Y.;Otomo K.;Sato Y.;Matsunaga T.;Takaishi A.;Miyagi N.;Uehara H.;Takaishi H.;Urata H.;Kataoka T.;Matsubara H.;Matsumoto T.;Suzuki T.;Takahashi N.;Imamaki M.;Yoshitama T.;Saito T.;Sekino H.;Furutani Y.;Koda M.;Shinozaki T.;Hirabayashi K.;Tsunoda R.;Yonezawa K.;Hori H.;Yagi M.;Arikawa M.;Hashizume T.;Ishiki R.;Koizumi T.;Nakayama K.;Taguchi S.;Nanasato M.;Yoshida Y.;Tsujiyama S.;Nakamura T.;Oku K.;Shimizu M.;Suwa M.;Momiyama Y.;Sugiyama H.;Kobayashi K.;Inoue S.;Kadokami T.;Maeno K.;Kawamitsu K.;Maruyama Y.;Nakata A.;Shibata T.;Wada A.;Cho H. -J.;Na J. O.;Yoo B. -S.;Choi J. -O.;Hong S. K.;Shin J. -H.;Cho M. -C.;Han S. H.;Jeong J. -O.;Kim J. -J.;Kang S. M.;Kim D. -S.;Kim M. H.;Llamas Esperon G.;Illescas Diaz J.;Fajardo Campos P.;Almeida Alvarado J.;Bazzoni Ruiz A.;Echeverri Rico J.;Lopez Alcocer I.;Valle Molina L.;Hernandez Herrera C.;Calvo Vargas C.;Padilla Padilla F. G.;Rodriguez Briones I.;Chuquiure Valenzuela E. J. J. R.;Aguilera Real M. E.;Carrillo Calvillo J.;Alpizar Salazar M.;Cervantes Escarcega J. L.;Velasco Sanchez R.;Al - Windy N.;van Heerebeek L.;Bellersen L.;Brunner-La Rocca H. -P.;Post J.;Linssen G. C. M.;van de Wetering M.;Peters R.;van Stralen R.;Groutars R.;Smits P.;Yilmaz A.;Kok W. E. M.;Van der Meer P.;Dijkmans P.;Troquay R.;van Alem A. P.;Van de Wal R.;Handoko L.;Westendorp I. C. D.;van Bergen P. F. M. M.;Rensing B. J. W. M.;Hoogslag P.;Kietselaer B.;Kragten J. A.;den Hartog F. R.;Alings A.;Danilowicz-Szymanowicz L.;Raczak G.;Piesiewicz W.;Zmuda W.;Kus W.;Podolec P.;Musial W.;Drelich G.;Kania G.;Miekus P.;Mazur S.;Janik A.;Spyra J.;Peruga J.;Balsam P.;Krakowiak B.;Szachniewicz J.;Ginel M.;Grzybowski J.;Chrustowski W.;Wojewoda P.;Kalinka A.;Zurakowski A.;Koc R.;Debinski M.;Fil W.;Kujawiak M.;Forys J.;Kasprzak M.;Krol M.;Michalski P.;Mirek-Bryniarska E.;Radwan K.;Skonieczny G.;Stania K.;Skoczylas G.;Madej A.;Jurowiecki J.;Firek B.;Wozakowska-Kaplon B.;Cymerman K.;Neutel J.;Adams K.;Balfour P.;Deswal A.;Djamson A.;Duncan P.;Hong M.;Murray C.;Rinde-Hoffman D.;Woodhouse S.;MacNevin R.;Rama B.;Broome-Webster C.;Kindsvater S.;Abramov D.;Barettella M.;Pinney S.;Herre J.;Cohen A.;Vora K.;Challappa K.;West S.;Baum S.;Cox J.;Jani S.;Karim A.;Akhtar A.;Quintana O.;Paukman L.;Goldberg R.;Bhatti Z.;Budoff M.;Bush E.;Potler A.;Delgado R.;Ellis B.;Dy J.;Fialkow J.;Sangrigoli R.;Ferdinand K.;East C.;Falkowski S.;Donahoe S.;Ebrahimi R.;Kline G.;Harris B.;Khouzam R.;Jaffrani N.;Jarmukli N.;Kazemi N.;Koren M.;Friedman K.;Herzog W.;Silva Enciso J.;Cheung D.;Grover-McKay M.;Hauptman P.;Mikhalkova D.;Hegde V.;Hodsden J.;Khouri S.;McGrew F.;Littlefield R.;Bradley P.;McLaurin B.;Lupovitch S.;Labin I.;Rao V.;Leithe M.;Lesko M.;Lewis N.;Lombardo D.;Mahal S.;Malhotra V.;Dauber I.;Banerjee A.;Needell J.;Miller G.;Paladino L.;Munuswamy K.;Nanna M.;McMillan E.;Mumma M.;Napoli M.;Nelson W.;O'Brien T.;Adlakha A.;Onwuanyi A.;Serota H.;Schmedtje J.;Paraschos A.;Potu R.;Sai-Sudhakar C.;Saltzberg M.;Sauer A.;Shah P.;Skopicki H.;Bui H.;Carr K.;Stevens G.;Tahirkheli N.;Tallaj J.;Yousuf K.;Trichon B.;Welker J.;Tolerico P.;Vest A.;Vivo R.;Wang X.;Abadier R.;Dunlap S.;Weintraub N.;Malik A.;Kotha P.;Zaha V.;Kim G.;Uriel N.;Greene T.;Salacata A.;Arora R.;Gazmuri R.;Kobayashi J.;Iteld B.;Vijayakrishnan R.;Dab R.;Mirza Z.;Marques V.;Nallasivan M.;Bensimhon D.;Peart B.;Saint-Jacques H.;Barringhaus K.;Contreras J.;Gupta A.;Koneru S.;Nguyen V.
2022
Abstract
Background: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients with HFrEF in addition to baseline treatment with specific doses and combinations of disease-modifying therapies. Methods: We performed a post-hoc analysis of the EMPEROR-Reduced randomised, double-blind, parallel-group trial, which took place in 520 centres (hospitals and medical clinics) in 20 countries in Asia, Australia, Europe, North America, and South America. Patients with New York Heart Association (NYHA) classification II–IV with an ejection fraction of 40% or less were randomly assigned (1:1) to receive the addition of either oral empagliflozin 10 mg per day or placebo to background therapy. The primary composite outcome was cardiovascular death and heart failure hospitalisation; the secondary outcome was total heart failure hospital admissions. An extended composite outcome consisted of inpatient and outpatient HFrEF events was also evaluated. Outcomes were analysed according to background use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs), as well as β blockers and mineralocorticoid receptor antagonists (MRAs) at less than 50% or 50% or more of target doses and in various combinations. This study is registered with ClinicalTrials.gov, NCT03057977. Findings: In this post-hoc analysis of 3730 patients (mean age 66·8 years [SD 11·0], 893 [23·9%] women; 1863 [49·9%] in the empagliflozin group, 1867 [50·1%] in the placebo group) assessed between March 6, 2017, and May 28, 2020, empagliflozin reduced the risk of the primary outcome (361 in 1863 participants in the empagliflozin group and 462 of 1867 in the placebo group; HR 0·75 [95% CI 0·65–0·86]) regardless of background therapy or its target doses for ACE inhibitors or ARBs at doses of less than 50% of the target dose (HR 0·85 [0·69–1·06]) and for doses of 50% or more of the target dose (HR 0·67 [0·52–0·88]; pinteraction=0·18). A similar result was seen for β blockers at doses of less than 50% of the target dose (HR 0·66 [0·54–0·80]) and for doses of 50% or more of the target dose (HR 0·81 [0·66–1·00]; pinteraction=0·15). Empagliflozin also reduced the risk of the primary outcome irrespective of background use of triple therapy with an ACE inhibitor, ARB, or ARNI plus β blocker plus MRA (given combination HR 0·73 [0·61–0·88]; not given combination HR 0·76 [0·62–0·94]; pinteraction=0·77). Similar patterns of benefit were observed for the secondary and extended composite outcomes. Empagliflozin was well tolerated and rates of hypotension, symptomatic hypotension, and hyperkalaemia were similar across all subgroups. Interpretation: Empagliflozin reduced serious heart failure outcomes across doses and combinations of disease-modifying therapies for HFrEF. Clinically, these data suggest that empagliflozin might be considered as a foundational therapy
Verma, S., Dhingra, N., Butler, J., Anker, S., Ferreira, J., Filippatos, G., et al. (2022). Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. THE LANCET DIABETES & ENDOCRINOLOGY, 10(1), 35-45 [10.1016/S2213-8587(21)00292-8].
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/373443
Citazioni
36
33
Social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 598/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
